Cutting the cost of South African antiretroviral therapy using newer, safer drugs

South African Medical Journal

Volumn 107, Issue 1, 2017, Pages 28-30

  Venter, W D F ^a   Kaiser, B ^b   Pillay, Y ^c   Conradie, F ^d   Gomez, G B ^e   Clayden, P ^f   Matsolo, M ^g   Amole, C ^h   Rutter, L ^g   Abdullah, F ⁱ   Abrams, E J ^j   Casas, C P ^b   Barnhart, M ^k   Pillay, A ^c   Pozniak, A ^l   Hill, A ^l   Fairlie, L ^a   Boffito, M ^l   Moorhouse, M ^a   Chersich, M ^a   Serenata, C ^a   Quevedo, J ^h   Loots, G ^m   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNITAID   (Switzerland)

^c NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^f c o HIV i Base   (United Kingdom)

^g Treatment Action Campaign   (South Africa)

^h CLINTON HEALTH ACCESS INITIATIVE   (United States)

ⁱ South African National AIDS Council (SANAC)   (South Africa)

^j Columbia University ^*  (United States)

^k UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^l CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^m French South African Technology Institute for Electronic Engineering   (South Africa)

more..

Author keywords

Antiretroviral therapy; Cost; Newer, safer drugs

Indexed keywords

CD4 ANTIBODY; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; GENERIC DRUG; LAMIVUDINE; RIFAMPICIN; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL;

ANTIVIRAL RESISTANCE; ARTICLE; COST MINIMIZATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PRIMARY HEALTH CARE; SOUTH AFRICAN; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 85007387770     PISSN: 02569574     EISSN: 20785135     Source Type: Journal    
DOI: 10.7196/SAMJ.2017.v107i1.12058     Document Type: Article

References (10)

1. National Department of Health and South African National AIDS Council. South African HIV and TB investment case-summary report phase 1. 2016. http://sanac.org.za/wp-content/uploads/2016/03/1603-Investment-Case-Report-LowRes-18-Mar.pdf (accessed 13 August 2016).
2. Surgey G, Cohen S, Guthrie T. Public health spending on antiretroviral medication in South Africa: An analysis of the annual ARV budget and expenditure for the financial year 2013/14, prepared for the South African National AIDS Council (in press).
3. South African Government News Agency. Tender to supply ARVs awarded to companies. 2015. http:// www.sanews.gov.za/south-africa/tender-supply-arvs-awarded-companies (accessed 17 September 2016).
4. Centre for Health Journalism. Health Minister Aaron Motsoaledi admits that ‘key leaders were in denial’. 2016. http://bhekisisa.org/article/2016-07-15-aids2016-health-minister-aaron-motsoaledi-admitsthat-key-leaders-were-in-denial/ (accessed 27 July 2016).
5. Clinton Health Access Initiative. ARV market report: The state of the antiretroviral drug market in low-and middle-income countries, 2014-2019. 2015. http://www.clintonhealthaccess.org/content/ uploads/2015/11/CHAI-ARV-Market-Report-2015_FINAL.pdf (accessed 27 July 2016).
6. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013;27(11):251. http://dx.doi.org/10.1186/1741-7015-11-251
7. Barnhart M, Shelton JD. ARVs: The next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Pract 2015;3(1):1-11. http://dx.doi.org/10.9745/GHSP-D-14-00243
8. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. http://issuu.com/ msf_access/docs/hiv_report_untangling-the-web-18the/25?e=3239302/37230248 (accessed 27 July 2016).
9. Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res 2016;pii:S0168-1702(16)30283-0. http://dx.doi.org/10.1016/j. virusres.2016.07.006
10. Vu L, Waliggo S, Zieman B, et al. Annual cost of antiretroviral therapy among three service delivery models in Uganda. J Int AIDS Soc 2016;20(19)(5 Suppl 4):20840. http://dx.doi.org/10.7448/IAS.19.5.20840